Adherium (ASX:ADR) share price rockets 53% on US FDA clearance

The company's shares are hitting a new 6-month high…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Adherium Ltd (ASX: ADR) share price soared to dizzying heights today. This comes after the digital healthcare company announced it has received a 510(k) clearance from the United States Food and Drug Administration (FDA).

At the end of Thursday's market close, Adherium shares finished up 53.33% to 2.3 cents.

A drawing of a white rocket streaking up, indicating a surging share pirce movement

Image source: Getty Images

Milestone achievement for Adherium

The Adherium share price surged today as investors were fighting to get a hold of the company's shares.

According to its release, Adherium advised that the United States FDA has cleared the pathway for the company to begin commercialisation for Hailie Sensor.

The company's next generation, Hailie Sensor are devices that attach to a patient's Asthma or Chronic Obstructive Pulmonary Disease (COPD) medication inhaler. This allows caregivers to monitor medication use and capture clinical data whilst supporting the patient's management and treatment journey.

Furthermore, the latest Hailie Sensor is designed for use with AstraZeneca's Symbicort aerosol inhaler.

The total addressable market for treating Asthma and COPD patients in the United States is estimated to be around US$1.5 billion.

With the Hailie Sensor approved, this means that the FDA has granted 10 510(k) licences to Adherium for its devices. As such, the company has become a market leader in respiratory digital health.

Adherium stated that it intends to pursue multiple channels in order for Hailie Sensor to enter the market.

Adherium CEO, Rick Legleiter commented:

The FDA's first clearance of our next generation Hailie sensors with physiological measures is a significant regulatory step for the business.

The stage is now set for physiological measures to be coupled with our existing adherence sensor capability giving us the total 'one-two punch' to deliver the best value proposition of any smart inhaler digital solution in the world.

…Adherium will expand its addressable respiratory medication market coverage and establish a preeminent business partnering position for providers, payors and digital health affiliates.

About the Adherium share price

Since this time last year, Adherium shares were mostly tracking lower until today, currently down 22%. Year-to-date, its shares are also in negative territory, down 14%.

Adherium presides a market capitalisation of roughly $54.3 million and has 2.1 billion shares on its registry.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Three excited business people cheer around a laptop in the office
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Legendary share market investing expert and owner of Berkshire Hathaway, Warren Buffett.
Opinions

3 ASX stocks that look like classic Warren Buffett investments

Here's why I think the Oracle of Omaha be interested in the ASX shares.

Read more »

Two happy shoppers looking at a smartphone together.
Share Market News

Why did ASX 200 retail shares outperform last week?

Wesfarmers, Light & Wonder, Nick Scali, and Temple & Webster shares surged 10% or more.

Read more »

Siblings laying upside down on a couch.
Opinions

2 ASX 200 shares I'd want my kids to own

These are two of my top picks right now.

Read more »

A man sits cross-legged in a zen pose on top of his desk as papers fly around his head, keeping calm amid the volatility.
Share Market News

What $500 a month in ASX ETFs looks like in 10 years

Boring, automatic, and relentless. That's how most everyday wealth actually gets built.

Read more »

A man in a suit looks serious while discussing business dealings with a couple as they sit around a computer at a desk in a bank home lending scenario.
Share Market News

Here's what Westpac says the RBA will do with interest rates next week

Is there another rate hike coming next week? Let's see what Australia's oldest bank is forecasting.

Read more »

A graphic image of a pile of gold coins balanced precariously with a house on top with smoke coming out of the chimney and a human figure with hands up as if to shield himself from the prospect of the house falling.
Broker Notes

This debt collector could surge 47% on negative gearing changes, Shaw and Partners says

A weaker housing market could be a boon for this company.

Read more »

Three young nerds dressed in suits with thinking caps and lightbulbs
Broker Notes

Brokers name 3 ASX shares to buy right now

Let's find out which shares top brokers are feeling bullish about this week.

Read more »